PolyPid (NASDAQ:PYPD) Given New $9.00 Price Target at Roth Capital

PolyPid (NASDAQ:PYPD) had its price target decreased by Roth Capital from $10.00 to $9.00 in a research report released on Thursday morning,Benzinga reports. Roth Capital currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on PYPD. Craig Hallum restated a “buy” rating and issued a $13.00 price objective (down from $15.00) on shares of PolyPid in a research note on Thursday, August 14th. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of PolyPid in a research report on Wednesday, August 13th. Wall Street Zen downgraded shares of PolyPid from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of PolyPid in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, PolyPid currently has an average rating of “Moderate Buy” and a consensus price target of $12.40.

PolyPid Stock Up 0.3%

Shares of PYPD stock traded up $0.01 during trading on Thursday, reaching $3.59. 8,473 shares of the company’s stock were exchanged, compared to its average volume of 89,583. The firm’s fifty day moving average price is $3.49 and its 200-day moving average price is $3.35. PolyPid has a twelve month low of $2.30 and a twelve month high of $3.93. The stock has a market capitalization of $57.08 million, a PE ratio of -1.20 and a beta of 1.53.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.17. As a group, analysts anticipate that PolyPid will post -1.79 EPS for the current fiscal year.

Institutional Trading of PolyPid

Several institutional investors and hedge funds have recently made changes to their positions in PYPD. AIGH Capital Management LLC grew its holdings in shares of PolyPid by 27.0% in the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after purchasing an additional 253,727 shares during the last quarter. Lumbard & Kellner LLC purchased a new stake in PolyPid in the 2nd quarter valued at about $135,000. Finally, BNP Paribas Financial Markets grew its stake in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares in the last quarter. 26.47% of the stock is currently owned by institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.